FDA panel rejects Pfizer’s arthritis drug as too risky
Fox News
U.S. health advisers sharply criticized an experimental arthritis drug Thursday, saying that it was too risky, even with limits on its use.
In studies, a small percentage of participants saw their joint damage get worse faster, sometimes requiring hip or knee replacements. Others had swelling or nerve damage. In some, healthy joints were damaged. "I’m concerned about the long-term side effects," said Dr. Lee D. Katz, a radiology expert at Yale University School of Medicine, citing the physician’s oath to "first do no harm."More Related News